(1417–1439) RA – Treatment Poster III

Sunday, November 13, 2022

1:00 PM – 3:00 PM Eastern Time

Location: Virtual Poster Hall

All of the relevant financial relationships listed for faculty have been mitigated.

Poster abstract session.

Presentations:

1:00 PM – 3:00 PM Eastern Time

Clinical and Demographic Characteristics of Patients with RF+/ACPA+ RA and First-Line TNF Inhibitor versus Abatacept Treatment Choice in Real-World Clinical Practice
Abstract Poster Presenter: Laetitia N'Dri, PharmD – BMS
1:00 PM – 3:00 PM Eastern Time

Change in Disease Activity and Occurrence of Adverse Events After Initiation of Etanercept in Pediatric Patients with Juvenile Psoriatic Arthritis in the CARRA Registry
Abstract Poster Presenter: Colleen Correll, MD, MPH – University of Minnesota
1:00 PM – 3:00 PM Eastern Time

Time to Discontinuation and Effectiveness with Baricitinib in Rheumatoid Arthritis: 12-Month European Data from a Multinational, Prospective, Observational Study
Abstract Poster Presenter: Rieke Alten, MD, PhD – SCHLOSSPARK KLINIK, University Medicine Berlin
1:00 PM – 3:00 PM Eastern Time

Outcomes in Patients with Rheumatoid Arthritis Initiating Monotherapy with Etanercept, Adalimumab, or Janus Kinase Inhibitors
Abstract Poster Presenter: Dimitrios Pappas, MD, MPH – CorEvitas
1:00 PM – 3:00 PM Eastern Time

Pharmacokinetics, Safety, Tolerability, and Immunogenicity of a Proposed Tocilizumab Biosimilar (MSB11456) versus US‑licensed Tocilizumab: Results of a Randomized, Double-blind, Parallel‑group, Single‑intravenous Dose Study in Healthy Adults (APTURA II)
Abstract Poster Presenter: Monika Tomaszewska-Kiecana – Biokinetica S.A.
1:00 PM – 3:00 PM Eastern Time

Incidence and Determinants of Infection in Rheumatoid Arthritis (RA) Patients (Pts) Treated with Subcutaneous Golimumab (GLM) in Canadian Real-World Practice
Abstract Poster Presenter: Louis Bessette, MD, MSc – Centre de l'Ostéoporose et de Rhumatologie de Québec
1:00 PM – 3:00 PM Eastern Time

Long-Term Treatment with Golimumab Is a Safe Treatment Option Regardless of Risk Factors in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Results from a Real-World Canadian Setting
Abstract Poster Presenter: Regan Arendse, PhD, FRCP, MBChB – Community Rheumatology Care
1:00 PM – 3:00 PM Eastern Time

Cost-Effectiveness of a Progressive Spacing of Tocilizumab or Abatacept in Patients with Rheumatoid Arthritis in Sustained Remission: A Medico-Economic Analysis of the ToLEDo Trial
Abstract Poster Presenter: Joanna Kedra, MD, MSc – IPLESP
1:00 PM – 3:00 PM Eastern Time

Treatment Persistence and Switching Patterns of ABP 501 (AMGEVITA^®) in German Patients with Rheumatic Diseases
Abstract Poster Presenter: Ran Jin, PhD – Amgen Inc.
1:00 PM – 3:00 PM Eastern Time

Year-two Follow-up Results of an Observational Study Conducted in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis Patients Treated with Infliximab Biosimilar CT-P13 in a Real-life Setting
Abstract Poster Presenter: Bruno Fautrel, MD, PhD – Sorbonne University - APHP
1:00 PM – 3:00 PM Eastern Time

Impact of Upadacitinib versus Abatacept on Individual Disease Outcomes in Patients with Rheumatoid Arthritis and Inadequate Responses to Biologic DMARDs
Abstract Poster Presenter: Ronald F. Van Vollenhoven, MD, PhD – Amsterdam UMC
1:00 PM – 3:00 PM Eastern Time

Molecular and Clinical Profiling of Rheumatoid Arthritis Patients Predicts the Response to Rituximab
Abstract Poster Presenter: Daniel Toro-Domínguez, Sr., PhD – GENYO
1:00 PM – 3:00 PM Eastern Time

Acute Cardiovascular Events Risk in Rheumatoid Arthritis Patients Treated with Tofacitinib or TNF Inhibitors, a Nationwide Cohort Study: RELATION Study
Abstract Poster Presenter: Jacques-Eric Gottenberg, PhD – CHU
1:00 PM – 3:00 PM Eastern Time

Time to First Remission and Prevalence of Sustained Remission After Etanercept Biosimilar (ETA-B) or Originator (ETA-O) Initiation in Rheumatoid Arthritis
Abstract Poster Presenter: Sasha Bernatsky, MD, PhD – Research Institute of the McGill University Health Centre
1:00 PM – 3:00 PM Eastern Time

Impact of Tofacitinib on Fracture Risk in Rheumatoid Arthritis
Abstract Poster Presenter: Giovanni Adami, MD – University of Verona, Italy
1:00 PM – 3:00 PM Eastern Time

Pharmacokinetic Evaluation of a Proposed Adalimumab Biosimilar MSB11022 versus the US-Licensed Reference Product: Results of a Randomized, Double-Blind, 3-Arm Parallel-Group, Single-Dose Trial in Healthy Subjects
Abstract Poster Presenter: Joëlle Monnet, MSc – Fresenius Kabi SwissBioSim
1:00 PM – 3:00 PM Eastern Time

A 48-week Analysis of a Pan-EU Real-world Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis
Abstract Poster Presenter: Ulf Müller-Ladner, MD – JLU Campus KK
1:00 PM – 3:00 PM Eastern Time

Retrospective Analysis of Tocilizumab-induced Neutropenia in Patients with Rheumatoid Arthritis
Abstract Poster Presenter: YoungEun Kim, MD – Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
1:00 PM – 3:00 PM Eastern Time

Effectiveness of Combination Therapy with Tocilizumab and Low-Dose Prednisolone as an Induction Therapy in Biologics-Naïve Patients with Rheumatoid Arthritis: A Prospective, Randomized, Controlled, Open-Label, Multicenter Study
Abstract Poster Presenter: Kazuhiro Yokota, MD, PhD – Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University
1:00 PM – 3:00 PM Eastern Time

Predictors at Diagnosis for Start of Biologic Disease Modifying Anti-Rheumatic Drugs in Patients with Early Rheumatoid Arthritis
Abstract Poster Presenter: Carl Turesson – Lund University
1:00 PM – 3:00 PM Eastern Time

WITHDRAWN
1:00 PM – 3:00 PM Eastern Time

The Ratio Between Biological and Glucocorticoid Use in Different Countries Worldwide: Results from the METEOR Registry
Abstract Poster Presenter: Isabell Nevins, PhD – LUMC
1:00 PM – 3:00 PM Eastern Time

Lymphatic Delivery of Etanercept Achieves Significant Improvements in Rheumatoid Arthritis Disease Measures at 50% of the Standard Dose for Patients with an Inadequate Response to Subcutaneous Injections
Abstract Poster Presenter: Russell Ross, PhD – Sorrento Therapeutics